Finkelstein Thompson LLP Announces Investigation of Medivation, Inc.
WASHINGTON--(BUSINESS WIRE)--Apr 9, 2010 - Finkelstein Thompson LLP announces that it is investigating potential shareholder derivative claims on behalf of Medivation, Inc. (Nasdaq:MDVN) (“Medivation” or the “Company”). On March 3, 2010, Medivation announced that its Alzheimer's drug Dimebon had failed to meet its co-primary or secondary efficacy endpoints compared to a placebo in a significant clinical trial, results which the Company claimed were “unexpected.” According to a recently-filed securities fraud class action, however, Medivation's management made false and misleading statements regarding the efficacy of Dimebon as a treatment for Alzheimer's disease from July 17, 2008 to March 2, 2010. The complaint also cites a leading Alzheimer's doctor from the University of Southern California who found that there was “nothing in [Dimebon's] structure to indicate it would have a remarkable effect” and that speculation that Dimebon would be the “next big thing” in treating Alzheimer's disease was not supported by “good evidence.”
If you are interested in discussing your rights as a Medivation shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, D.C. offices at (877) 337-1050 or by email at firstname.lastname@example.org.
Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.
To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Finkelstein Thompson LLP
Donald Enright, 202-337-8000
Posted: April 2010